Free Trial

Indiva (NDVA) Stock Forecast & Price Target

C$0.03
-0.01 (-14.29%)
(As of 06/12/2024)

Indiva - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 1 Wall Street analysts who have issued ratings for Indiva in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for NDVA.

Consensus Price Target

C$0.15
400.00% Upside
High ForecastC$0.15
Average ForecastC$0.15
Low ForecastC$0.15

According to the 1 analysts' twelve-month price targets for Indiva, the average price target is C$0.15. The highest price target for NDVA is C$0.15, while the lowest price target for NDVA is C$0.15. The average price target represents a forecasted upside of 400.00% from the current price of C$0.03.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price TargetC$0.15C$0.15C$0.15N/A
Forecasted Upside400.00% Upside30.43% Upside30.43% UpsideN/A
Get Indiva Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NDVA and its competitors with MarketBeat's FREE daily newsletter.

NDVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NDVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Indiva Stock vs. The Competition

TypeIndivaMedical Companies
Consensus Rating Score
3.00
2.72
Consensus RatingBuyModerate Buy
News Sentiment RatingNeutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/5/2024Echelon Wealth Partners
1 of 5 stars
 Boost TargetSpeculative BuyC$0.13 ➝ C$0.15+30.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:40 AM ET.

NDVA Forecast - Frequently Asked Questions

What is Indiva's forecast for 2024?

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Indiva is C$0.15, with a high forecast of C$0.15 and a low forecast of C$0.15.

Should I buy or sell Indiva stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indiva in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NDVA shares.

Does Indiva's stock price have much upside?

According to analysts, Indiva's stock has a predicted upside of 30.43% based on their 12-month stock forecasts.

Do Wall Street analysts like Indiva more than its competitors?

Analysts like Indiva more than other "medical" companies. The consensus rating for Indiva is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NDVA compares to other companies.


Related Companies:
This page (CVE:NDVA) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners